Flavonoids are a class of plant and fungus secondary metabolites that serve functional roles in protecting against UV-induced oxidative stress, mediating auxin signaling, and promoting microbial defense. Flavonoids are extremely abundant in nature where their potent antioxidant capacity and very low toxicity makes them highly attractive as potential therapeutic agents. In terms of clinical applications, neither the Food and Drug Administration (FDA) nor the European Food Safety Authority (EFSA) has approved any health claims or drugs related to the use of flavonoids for therapeutic purposes. Quercetin is a common flavonol that has been shown to have potent antioxidant, anti-inflammatory, and anti-fibrotic activities both in vitro and in vivo in various tissues. Recently, the application of quercetin as a therapeutic has been gaining attention in the ocular surface scientific community in the study of dry eye, keratoconus, inflammation, and neovascularization of the cornea. This review will discuss the latest findings and the use of quercetin for the treatment of dystrophies of the ocular surface.
Impact statement
The eye represents a small portion of the human body, accounting for one decimal fraction of the anterior body surface. The cornea is an avascular, transparent tissue that acts as a primary barrier against mechanical and infectious damaging agents, protecting the internal structures of the eye. Corneal survival and function are affected by a number of factors including but not limited to injury, trauma, infection, genetics, and environment. Corneal injury, or trauma, often leads to loss of corneal transparency and even blindness. The concept of “curing” corneal opacity has been discussed in published form for over 200 years. Currently, full corneal transplant is the only treatment option. There is a strong interest in developing natural therapeutic products that come with minimum side effects. A novel antioxidant flavonoid, quercetin, has been gaining traction as a potential therapeutic to prevent the injured cornea. This review discusses the potential of this antioxidant.
HerrmannK. Flavonols and flavones in food plants: A review†. Int J Food Sci Technol1976; 11: 433–48.
2.
HarborneJB. The flavonoids: Advances in research since 1980, New York: Springer, 1988.
3.
RossiMRicklesLFHalpinWA. The crystal and molecular structure of quercetin: A biologically active and naturally occurring flavonoid. Bioorganic Chem1986; 14: 55–69.
4.
CaoGSoficEPriorRL. Antioxidant and prooxidant behavior of flavonoids: Structure-activity relationships. Free Rad Biol Med1997; 22: 749–60.
5.
VinsonJADabbaghYASerryMMJangJ. Plant flavonoids, especially tea flavonols, are powerful antioxidants using an in vitro oxidation model for heart disease. J Agri Food Chem1995; 43: 2800–2.
6.
AviramMDornfeldLKaplanMColemanRGaitiniDNiteckiSHofmanARosenblatMVolkovaNPresserDAttiasJHayekTFuhrmanB. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: Studies in atherosclerotic mice and in humans. Drugs Under Exp Clin Res2001; 28: 49–62.
7.
OnozukaHNakajimaAMatsuzakiKShinR-WOginoKSaigusaDTetsuNYokosukaASashidaYMimakiYYamakuniTOhizumiY. Nobiletin, a citrus flavonoid, improves memory impairment and Aβ pathology in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther2008; 326: 739–44.
8.
HertogMGFeskensEJKromhoutDHollmanPKatanM. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet1993; 342: 1007–11.
9.
RimmEBKatanMBAscherioAStampferMJWillettWC. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Int Med1996; 125: 384–9.
NishimuroHOhnishiHSatoMOhnishi-KameyamaMMatsunagaINaitoSIppoushiKOikeHNagataTAkasakaHSaitohSShimamotoKKoboriM. Estimated daily intake and seasonal food sources of quercetin in Japan. Nutrients2015; 7: 2345–58.
12.
HollmanPCHKatanMB. Dietary flavonoids: Intake, health effects and bioavailability. Food Chem Toxicol1999; 37: 937–42.
13.
NemethKPiskulaM. Food content, processing, absorption and metabolism of onion flavonoids. Crit Rev Food Sci Nutr2007; 47: 397–409.
14.
CasagrandeRGeorgettiSRVerriWADortaDJdos SantosACFonsecaMJ. Protective effect of topical formulations containing quercetin against UVB-induced oxidative stress in hairless mice. J Photochem Photobiol B: Biol2006; 84: 21–7.
15.
VicentiniFTSimiTRDel CiampoJOWolgaNOPitolDLIyomasaMMBentleyaVLBFonsecaaMJV. Quercetin in w/o microemulsion: In vitro and in vivo skin penetration and efficacy against UVB-induced skin damages evaluated in vivo. Eur J Pharm Biopharm2008; 69: 948–57.
16.
Winkel-ShirleyB. Flavonoid biosynthesis. A colorful model for genetics, biochemistry, cell biology, and biotechnology. Plant Physiol2001; 126: 485–93.
17.
Winkel-ShirleyB. Biosynthesis of flavonoids and effects of stress. Curr Opinion Plant Biol2002; 5: 218–23.
18.
GrootHdRauenU. Tissue injury by reactive oxygen species and the protective effects of flavonoids. Fund Clin Pharmacol1998; 12: 249–55.
ManachCWilliamsonGMorandCScalbertARémésyC. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr2005; 81: 230S–42.
21.
HollmanPDe VriesJvan LeeuwenSDMengelersMKatanMB. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr1995; 62: 1276–82.
22.
MurotaKTeraoJ. Antioxidative flavonoid quercetin: Implication of its intestinal absorption and metabolism. Arch Biochem Biophys2003; 417: 12–7.
23.
DayAJMellonFBarronDSarrazinGMorganMRWilliamsonG. Human metabolism of dietary flavonoids: Identification of plasma metabolites of quercetin. Free Rad Res2001; 35: 941–52.
24.
JanischKMWilliamsonGNeedsPPlumbGW. Properties of quercetin conjugates: Modulation of LDL oxidation and binding to human serum albumin. Free Rad Res2004; 38: 877–84.
25.
WittigJHerderichMGraefeEUVeitM. Identification of quercetin glucuronides in human plasma by high-performance liquid chromatography–tandem mass spectrometry. J Chromatograph B2001; 753: 237–43.
26.
BeuermanRWPedrozaL. Ultrastructure of the human cornea. Microscopy Res Tech1996; 33: 320–35.
27.
StockerFW. The endothelium of the cornea and its clinical implications. Transac Am Ophthal Soc1953; 51: 669–669.
LiFCarlssonDLohmannCSuuronenEVascottoSKobuchKSheardownHMungerRNakamuraMGriffithM. Cellular and nerve regeneration within a biosynthetic extracellular matrix for corneal transplantation. Proc Natl Acad Sci2003; 100: 15346–51.
30.
LiuYGanLCarlssonDJFagerholmPLagaliNWatskyMAMungerRHodgeWGPriestDGriffithM. A simple, cross-linked collagen tissue substitute for corneal implantation. Investigative ophthalmology & visual science2006; 47(5): 1869–75.
31.
LeeVHRobinsonJR. Topical ocular drug delivery: Recent developments and future challenges. J Ocular Pharmacol Therap1986; 2: 67–108.
32.
DaviesNM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol2000; 27: 558–62.
33.
ChallaRAhujaAAliJKharR. Cyclodextrins in drug delivery: An updated review. Aaps Pharmscitech2005; 6: E329–57.
34.
FinkelT. Signal transduction by reactive oxygen species in non-phagocytic cells. J Leukocyte Biol1999; 65: 337–40.
35.
FialkowLWangYDowneyGP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Rad Biol Med2007; 42: 153–64.
36.
FadeelBÅhlinAHenterJ-IOrreniusSHamptonMB. Involvement of caspases in neutrophil apoptosis: Regulation by reactive oxygen species. Blood1998; 92: 4808–18.
37.
Ushio-FukaiMNakamuraY. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett2008; 266: 37–52.
38.
XiaCMengQLiuL-ZRojanasakulYWangX-RJiangB-H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res2007; 67: 10823–30.
39.
TaniyamaYGriendlingKK. Reactive oxygen species in the vasculature molecular and cellular mechanisms. Hypertension2003; 42: 1075–81.
40.
HsuH-YWenM-H. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem2002; 277: 22131–9.
41.
SenCKPackerL. Antioxidant and redox regulation of gene transcription. FASEB J1996; 10: 709–20.
42.
GloireGLegrand-PoelsSPietteJ. NF-κB activation by reactive oxygen species: Fifteen years later. Biochem Pharmacol2006; 72: 1493–505.
43.
MinY-DChoiC-HBarkHSonH-YParkH-HLeeSParkJ-WParkE-KShinH-IKimS-H. Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-κB and p38 MAPK in HMC-1 human mast cell line. Inflamm Res2007; 56: 210–5.
RogerioAKanashiroAFontanariCDa SilvaELucisano-ValimYSoaresEFaccioliLH. Anti-inflammatory activity of quercetin and isoquercitrin in experimental murine allergic asthma. Inflamm Res2007; 56: 402–8.
46.
NickelTHanssenHSisicZPfeilerSSummoCSchmaussDHosterEWeisM. Immunoregulatory effects of the flavonol quercetin in vitro and in vivo. Eur J Nutr2011; 50: 163–72.
ZhaoDQinCFanXLiYGuB. Inhibitory effects of quercetin on angiogenesis in larval zebrafish and human umbilical vein endothelial cells. Eur J Pharmacol2014; 723: 360–7.
49.
LjubimovAVCaballeroSAokiAMPinnaLAGrantMBCastellonR. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthal Visual Sci2004; 45: 4583–91.
50.
SarnoSRuzzeneMFrascellaPPaganoMAMeggioFZambonAMarco Mazzorana, MairaGDLucchiniVPinnaLA. Development and exploitation of CK2 inhibitors. Mol Cell Biochem2005; 274: 69–76.
51.
SarnoSMoroSMeggioFZagottoGDal BenDGhiselliniPBattistuttadRZanottidGPinnaLA. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther2002; 93: 159–68.
52.
Landesman-BollagERomieu-MourezRSongDHSonensheinGECardiffRDSeldinDC. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene2001; 20: 3247–57.
53.
DuncanJSLitchfieldDW. Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta2008; 1784: 33–47.
54.
ElAttarTMVirjiAS. Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anti-Cancer Drugs1999; 10: 187–94.
55.
MurakamiAAshidaHTeraoJ. Multitargeted cancer prevention by quercetin. Cancer Lett2008; 269: 315–25.
56.
LolliGCozzaGMazzoranaMTibaldiECesaroLDonella-DeanaAMeggioFVenerandoAFranchinCSarnoSBattistuttaRPinnaLA. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry2012; 51: 6097–107.
57.
Abengózar-VelaACalongeMSternMEGonzález-GarcíaMJEnríquez-De-SalamancaA. Quercetin and resveratrol decrease the inflammatory and oxidative responses in human ocular surface epithelial cells. Invest Ophthal Visual Sci2015; 56: 2709–19.
58.
Abengózar-VelaASchaumburgCSSternMECalderVLCalongeMEnriquez-De-SalamancaAGonzalezM-JJ. An in vivo study of anti-inflammatory effect of Quercetin and Resveratrol polyphenols in a desiccating stress mouse model of dry eye. Invest Ophthal Visual Sci2014; 55: 3654–3654.
59.
OhHNKimCELeeJHYangJW. Effects of quercetin in a mouse model of experimental dry eye. Cornea2015; 34: 1130–6.
60.
DonniniSFinettiFLusiniLMorbidelliLCheynierVBarronDWilliamsonGWaltenbergerJZicheM. Divergent effects of quercetin conjugates on angiogenesis. Br J Nutr2006; 95: 1016–23.
61.
HaynesWProiaADKlintworthG. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthal Visual Sci1989; 30: 1588–93.
62.
KoboriMMasumotoSAkimotoYOikeH. Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice. Mol Nutr Food Res2011; 55: 530–40.
63.
SnyderSMZhaoBLuoTKaiserCCavenderG. Consumption of quercetin and quercetin-containing apple and cherry extracts affects blood glucose concentration, hepatic metabolism, and gene expression patterns in obese C57BL/6J high fat-fed mice. J Nutr2016; 146: 1001–7.
64.
ZhangMXieZGaoWPuLWeiJGuoC. Quercetin regulates hepatic cholesterol metabolism by promoting cholesterol-to-bile acid conversion and cholesterol efflux in rats. Nutr Res2016; 36: 271–9.
65.
KoboriMMasumotoSAkimotoYTakahashiY. Dietary quercetin alleviates diabetic symptoms and reduces streptozotocin-induced disturbance of hepatic gene expression in mice. Mol Nutr Food Res2009; 53: 859–68.
66.
MukhopadhyayPPrajapatiA. Quercetin in anti-diabetic research and strategies for improved quercetin bioavailability using polymer-based carriers – A review. RSC Adv2015; 5: 97547–62.
67.
LeeVChienDSasakiH. Ocular ketone reductase distribution and its role in the metabolism of ocularly applied levobunolol in the pigmented rabbit. J Pharmacol Exp Ther1988; 246: 871–8.
68.
StoddardARKoetjeLRMitchellAKSchotanusMPUbelsJL. Bioavailability of antioxidants applied to stratified human corneal epithelial cells. J Ocul Pharmacol Ther2013; 29: 681–7.
69.
MathersWDLaneJAZimmermanMB. Tear film changes associated with normal aging. Cornea1996; 15: 229–34.
70.
ChwaMAtilanoSRHertzogDZhengHLangbergJKimDWKenneyMC. Hypersensitive response to oxidative stress in keratoconus corneal fibroblasts. Invest Ophthal Visual Sci2008; 49: 4361–9.
71.
ChwaMAtilanoSRReddyVJordanNKimDWKenneyMC. Increased stress-induced generation of reactive oxygen species and apoptosis in human keratoconus fibroblasts. Invest Ophthal Visual Sci2006; 47: 1902–10.
72.
KenneyMCBrownDJ. The cascade hypothesis of keratoconus. Cont Lens Anterior Eye2003; 26: 139–46.
73.
KenneyMCChwaMAtilanoSRTranACarballoMSaghizadehMVasiliouVAdachiWBrownDJ. Increased levels of catalase and cathepsin V/L2 but decreased TIMP-1 in keratoconus corneas: Evidence that oxidative stress plays a role in this disorder. Invest Ophthal Visual Sci2005; 46: 823–32.
74.
KaramichosDHutcheonARichCTrinkaus-RandallVAsaraJZieskeJ. In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep2014; 4: 4608–4608.
75.
Sarker-NagAHutcheonAEKaramichosD. Mitochondrial Profile and Responses to TGF-β Ligands in Keratoconus. Curr Eye Res2016; 41: 900–7.
76.
AtilanoSRCoskunPChwaMJordanNReddyVLeKWallaceDCKenneyMC. Accumulation of mitochondrial DNA damage in keratoconus corneas. Invest Ophthal Visual Sci2005; 46: 1256–63.
77.
Abu-AmeroKKAzadTAKalantanHSultanTAl-MuammarAM. Mitochondrial sequence changes in keratoconus patientsscreening mitochondrial genome in keratoconus patients. Invest Ophthal Visual Sci2014; 55: 1706–10.
McKayTLyonDSarker-NagAPriyadarsiniSAsaraJKaramichosD. Quercetin attenuates lactate production and extracellular matrix secretion in keratoconus. Sci Rep2015; 5: 9003–9003.
80.
WhitcherJPSrinivasanMUpadhyayMP. Corneal blindness: A global perspective. Bull World Health Org2001; 79: 214–21.
81.
WilsonSEMohanRRMohanRRAmbrosioRHongJWLeeJS. The corneal wound healing response: Cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res2001; 20: 625–37.
82.
SchultzGSWysockiA. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen2009; 17: 153–62.
83.
BarrJTWilsonBSGordonMORahMJRileyCKollbaumPSZadnikK. Estimation of the incidence and factors predictive of corneal scarring in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study. Cornea2006; 25: 16–25.
84.
TsengSCLiDQMaX. Suppression of transforming growth factor-beta isoforms, TGF-β receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol1999; 179: 325–35.
85.
GuptaAGHirakataAProiaAD. Effect of inhibitors of arachidonic acid metabolism on corneal reepithelialization in the rat. Exp Eye Res1993; 56: 701–8.
86.
MajmudarPAForstotSLDennisRFNirankariVSDamianoREBrenartREpsteinRJ. Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology2000; 107: 89–94.
87.
LambiaseARamaPBoniniSCaprioglioGAloeL. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med1998; 338: 1174–80.
TsubotaKSatakeYKaidoMShinozakiNShimmuraSBissen-MiyajimaHShimazakiJ. Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation. N Engl J Med1999; 340: 1697–703.
90.
GainPJullienneRHeZAldossaryMAcquartSCognasseFThuretG. Global survey of corneal transplantation and eye banking. JAMA Ophthal2016; 134: 167–73.
91.
GargPKrishnaPStratisAGopinathanU. The value of corneal transplantation in reducing blindness. Eye2005; 19: 1106–14.
92.
YoonJSChaeMKJangSYLeeSYLeeEJ. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of graves' orbitopathyantifibrotic effects of quercetin in GO. Invest Ophthal Visual Sci2012; 53: 5921–9.
93.
LuNTCrespiCMLiuNMVuJQAhmadiehYWuSLinSMcCluneADurazoFSaabSHanSNeimanDCBeavenSFrenchSW. A phase I dose escalation study demonstrates quercetin safety and explores potential for bioflavonoid antivirals in patients with chronic hepatitis C. Phytother Res2016; 30: 160–8.
94.
ValensiPLe DevehatCRichardJ-LFarezCKhodabandehlouTRosenbloomRALeFanteC. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy: A preliminary report. J Diab Complicat2005; 19: 247–53.
